Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Buspirone→

Buspirone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
36505-84-7
Molecular formula
C21H31N5O2
Molecular weight
385.5 g/mol
Drug class
Azapirone anxiolyticpartial agonist at serotonin 5-HT1A receptors
Mechanism of action
Acts primarily as a partial agonist at central 5-HT1A receptors, modulating serotonergic neurotransmission. It has lower sedative, muscle-relaxant and dependence potential than benzodiazepines and does not act as a GABAA receptor positive allosteric modulator.
Indications / reported uses
  • Treatment of anxiety disorders or short-term relief of symptoms of anxiety in adults under the US product indication; it is not intended for immediate relief of acute anxiety episodes

Sources: US DailyMed — Buspirone hydrochloride · NLM MeSH — Buspirone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Buspirone Environmental Risk Assessment (ERA) (the Buspirone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.